CABA vs KYTX
CABA: Cabaletta Bio is a clinical-stage biotechnology firm developing one-time, curative CAR T cell therapies aimed at resetting the immune system for patients with complex autoimmune diseases. KYTX: Kyverna is a clinical-stage immunology biotech developing novel investigational therapeutics with no approved products and complete dependence on successful clinical trial outcomes.
Side-by-side fundamentals
| Metric | CABA | KYTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.75 | $7.40 | |
| Market cap as of 2026-07-23 | $449M | $452M | |
| Net margin as of 2026-07-23 | n/a | -411.3% | |
| Operating margin as of 2026-07-23 | n/a | -418.3% | |
| ROE as of 2026-07-23 | -131.6% | -81.9% | KYTX higher |
| ROA as of 2026-07-23 | -96.5% | -64.9% | KYTX higher |
| Debt / equity as of 2026-07-23 | 0.23 | 0.13 | KYTX lower |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-23 | 3.27 | 1.88 | |
| 1-year return as of 2026-07-22 close | +72.0% | +93.3% | KYTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.